Trial intelligence / Profile preview

SELECT-SWITCH: upadacitinib versus adalimumab in rheumatoid arthritis after inadequate response or intolerance to one TNF inhibitor

CTR20232773Phase 3Active

Sponsor

AbbVie Inc.

Start

Jun 2024

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules

Countries

1